Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration-Reference-Cited by-同舟云学术

Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration

Published:2007-08 Issue:4 Volume:102 Page:1001-1008
ISSN:0022-3042
Container-title:Journal of Neurochemistry
language:en
Short-container-title:J Neurochem

Author:

Buttmann Mathias,Lorenz Alexander,Weishaupt Andreas,Rieckmann Peter

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1471-4159.2007.04563.x/fullpdf

Reference33 articles.

1. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack

2. Protective Effects of Statins Involving Both eNOS and tPA in Focal Cerebral Ischemia

3. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations

4. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the CCL2–CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases;Journal of Pharmacy and Pharmacology;2023-12-21

2. Potential impact of high-density lipoprotein cholesterol in the postoperative outcomes of chronic subdural hematoma patients: multi-institutional study in Korea;Lipids in Health and Disease;2023-11-17

3. Trypanosoma brucei rhodesiense Inhibitor of Cysteine Peptidase (ICP) Is Required for Virulence in Mice and to Attenuate the Inflammatory Response;International Journal of Molecular Sciences;2022-12-30

4. Atorvastatin for unruptured intracranial vertebrobasilar dissecting aneurysm (ATREAT-VBD): protocol for a randomised, double-blind, blank-controlled trial;BMJ Open;2022-04

5. Risk Factor Analysis of the Conservative Treatment in Chronic Subdural Hematomas: A Substudy of the ATOCH Trial;Advances in Therapy;2022-02-08